PRGO:NYE-Perrigo Company plc

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 45.97

Change

0.00 (0.00)%

Market Cap

USD 6.25B

Volume

1.41M

Average Target Price

USD 69.71 (51.65%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-19 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

N/A

USD 350.51B
PFE Pfizer Inc.

N/A

USD 245.84B
NVS Novartis AG

N/A

USD 205.57B
MRK Merck & Company Inc. (new)

N/A

USD 197.29B
ABBV AbbVie Inc.

N/A

USD 134.63B
LLY Eli Lilly and Company

N/A

USD 123.51B
GSK GlaxoSmithKline PLC

N/A

USD 96.96B
AZN Astrazeneca PLC

N/A

USD 92.62B
BMY Bristol-Myers Squibb Company

N/A

USD 81.82B
TAK Takeda Pharmaceutical Company ..

N/A

USD 61.38B

ETFs Containing PRGO

KLDW Knowledge Leaders Develop.. 0.00 % 0.75 %

N/A

USD 6.23M
GNRX Market Vectors Generic Dr.. 0.00 % 0.55 %

N/A

USD 3.26M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.63% 73% C 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.63% 73% C 91% A-
Trailing 12 Months  
Capital Gain -49.97% 11% F 4% F
Dividend Return 0.83% 17% F 12% F
Total Return -49.14% 11% F 4% F
Trailing 5 Years  
Capital Gain -70.54% 12% F 6% F
Dividend Return 1.86% 7% F 7% F
Total Return -68.68% 12% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -12.70% 21% F 7% F
Dividend Return -12.16% 16% F 6% F
Total Return 0.54% 27% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 26.65% 32% F 22% F
Risk Adjusted Return -45.64% 5% F 8% F
Market Capitalization 12.59B 35% F 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.08 27% F 9% F
Price/Book Ratio 1.06 80% B- 62% D-
Price / Cash Flow Ratio 2.61 60% D- 48% F
Price/Free Cash Flow Ratio 12.16 58% F 47% F
Management Effectiveness  
Return on Equity 2.05% 31% F 28% F
Return on Invested Capital 5.90% 38% F 36% F
Return on Assets 1.08% 38% F 35% F
Debt to Equity Ratio 55.50% 56% F 58% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector